Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceutical Drug Discovery & Development (Miscellaneous)
Kojin Therapeutics

Finance & Acquisition: Kojin Therapeutics

Parents

2021: Kojin Therapeutics gets $60 million to explore ferroptosis _ i22
2021: Kojin Therapeutics Launches with $60 Million Series A to Develop New Category of Drugs Based on Cell State Biology
2021: Series A led by Polaris Partners, Newpath Partners, and Cathay Health, affiliated to Cathay Capital, with participation from Leaps by Bayer, AbbVie Inc., Eventide Asset Management, Alexandria, the Dana-Farber Cancer Institute’s Binney Street Capital, and several family offices.